DescriptionAurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.
Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.
A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.
What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.
A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 17.23 +15.15% increase |
| 20.52 -3.31% decrease |
| +0.11 (+0.56%) increase |
|3-Month|| 17.09 +16.09% increase |
| 22.65 -12.41% decrease |
| -2.67 (-11.86%) decrease |
|52-Week|| 4.70 +322.13% increase |
| 28.59 -30.61% decrease |
| +11.70 (+143.73%) increase |